European Society of Cardiology (ESC) Congress 2021 (August 27-30, 2021 - Virtual Meeting).

The 2021 Congress of the European Society of Cardiology (ESC) was again held as a digital experience, providing poster and oral sessions highlighting the latest developments in cardiovascular science, including therapeutics for a range of related conditions and updates on ongoing trials, as well as guideline updates.

The European League Against Rheumatism (EULAR) - 17th Annual European Congress of Rheumatology (June 8-11, 2016 - London, UK).

The 2016 Annual European Congress of Rheumatology, an annual conference organized by the European League Against Rheumatism (EULAR), took place in London, U.K. Over 4,000 abstracts were submitted this year with over 199 sessions and poster tours on offer.

American Urological Association (AUA) - 111th Annual Meeting (May 6-10, 2016 - San Diego, California, USA).

The 111(th) Annual Meeting of the American Urological Association (AUA) brought together a wide range of researchers in the field of urology to share knowledge and set standards in urological research. The meeting consisted of plenary, podium and moderated poster sessions, in which the latest research and advances in urologic medicine were presented. This report will highlight some of the presentations on therapeutic developments for a range of urological conditions.

A report from the American college of rheumatology/association of rheumatology health professionals (ACR/ARHP) - 2012 annual meeting (November 9-14, 2012 - Washington, D.C., USA).

The annual meeting of the American College of Rheumatology (ACR), jointly held with the Association of Rheumatology Health Professionals (ARHP), brought together attendees focused on all aspects of rheumatology, including researchers looking into treatment options and various services around the care of rheumatologic conditions. As well as networking opportunities at the meeting, there were a wide range of symposia and posters available covering various conditions and levels of research. There were also educational and meet-the-professor sessions.

American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 2.

The American Diabetes Association 70th Scientific Sessions, held in Orlando, FL, USA, included topics covering new therapeutic developments in the field of diabetes research. This conference report highlights selected presentations on new research with novel agents. Investigational drugs discussed include the glucokinase activator SKL-19014 (Sanwa Kagaku Kenkyusho Co Ltd), the GPR119 agonist AS-1535907 (Astellas Pharma Inc), the apical sodium-dependent bile transporter (ASBT) inhibitor SC-435 (Satiogen Pharmaceuticals Inc), the VEGF-A activator SB-509 (Sangamo BioSciences Inc), and the protein tyrosine phosphatase 1b (PTP-1b) antisense inhibitor ISIS-113715 (ISIS Pharmaceuticals Inc).

American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 1.

The American Diabetes Association 70th Scientific Sessions, held in Orlando, FL, USA, included topics covering new therapeutic developments in the field of diabetes research. This conference report highlights selected presentations on new research with novel agents. Investigational drugs discussed include the glucagon-like peptide-1 (GLP-1) agonist taspoglutide (Roche Holding AG/Teijin Ltd/ Chugai Pharmaceutical Co Ltd), the GLP-1 analog SKL-18287 (Sanwa Kagaku Kenkyusho Co Ltd), the sodium glucose transporter-2 (SGLT2) inhibitor ASP-1941 (Astellas Pharma Inc/Kotobuki Pharmaceutical Co Ltd), the dual SGLT2/1 inhibitor LX-4211 (Lexicon Pharmaceuticals Inc), and the selective PPARgamma modulator INT-131 (InteKrin Therapeutics Inc).

28th Annual JPMorgan Healthcare Conference--Forest Laboratories and Icagen.

The JPMorgan Healthcare conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing their achievements in 2009 and expectations for 2010. This conference report highlights presentations from Forest Laboratories Inc and Icagen Inc. Investigational drugs from Forest Laboratories, including roflumilast (in collaboration with Nycomed Inc/Mitsubishi Tanabe Pharma Corp), ceftaroline fosamil (with AstraZeneca plc), linaclotide (with Ironwood Pharmaceuticals Inc/Astellas Pharma Inc/Almirall Prodesfarma SA), cariprazine (with Gedeon Richter Ltd/Mitsubishi Tanabe Pharma Corp), aclidinium bromide (with Almirall), dutogliptin (with Phenomix Corp/Chiesi Farmaceutici SpA) and levomilnacipran (with Pierre Fabre SA), and from Icagen, including ICA-105665, are discussed.

28th Annual JPMorgan Healthcare Conference--Affymax and Infinity Pharmaceuticals.

The JP Morgan Healthcare Conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing their achievements in 2009 and expectations for 2010. This conference report highlights presentations from Affymax Inc and Infinity Pharmaceuticals Inc. Investigational drugs from Affymax, including Hematide (in collaboration with Takeda Pharmaceutical Co Ltd), and from Infinity Pharmaceuticals, including IPI-926, retaspimycin hydrochloride, IPI-493 and IPI-940, are discussed.

28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics.

The JPMorgan Healthcare Conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing their achievements in 2009 and expectations for 2010. This conference report highlights presentations from Exelixis Inc and Nektar Therapeutics. Investigational drugs from Exelixis, including XL-184 (in collaboration with Bristol-Myers Squibb Co), XL-147 and XL-765 (both in collaboration with sanofi-aventis), and from Nektar, including NKTR-118 and NKTR-119 (both now licensed to AstraZeneca plc), NKTR-171, NKTR-181, NKTR-194, NKTR-102, and NKTR-105, are discussed.

28th Annual JPMorgan Healthcare Conference--Human Genome Sciences and Celgene.

The JPMorgan Healthcare Conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing their achievements in 2009 and expectations for 2010. This conference report highlights presentations from Human Genome Sciences Inc and Celgene Corp. Investigational drugs from Human Genome Sciences, including belimumab (in collaboration with GlaxoSmithKline plc), albinterferon alfa-2b (with Novartis AG), mapatumumab (with Takeda Pharmaceutical Co Ltd) and HGS-1029, and from Celgene, including romidepsin, pomalidomide, apremilast and PDA-001 (Celgene Cellular Therapeutics), are discussed.